August 27, 2024

HTA Quarterly Fall 2024

By AmerisourceBergen

In this special themed edition, our colleagues at Vintura, a Cencora company, explore the potential of value-based partnerships (VBPs). First outlining the principles, goals, and potential benefits of VBPs, this edition also provides two case studies that demonstrate how successful partnerships work in practice.

Subscribe to HTA Quarterly

Embracing value-based partnerships: A path to enhanced healthcare outcomes

Understand when value-based partnerships in healthcare create the most impact for patients, and learn how to forge those alliances.

“Harmonizing methodological choices between drug developers and assessors presents a promising avenue towards enhancing accuracy and reliability in HTAs.”

Dr. Michael Hennig, Senior Director, Expertise Line Head for HTA Statistics at PharmaLex, a Cencora company, comments on the new EU guidelines on statistical analysis set to impact biopharmaceutical companies starting in January 2025.

Source: Q&A on the latest guidelines for statistical analysis in EU Health Technology Assessment (amerisourcebergen.com)

By the numbers

9% - The price of confidentiality

Under the German Medical Research Act (MFG), which will come into effect on January 1, 2025, pharma companies with R&D departments in Germany will be able to choose between transparent or confidential pricing. Those who choose the confidential option agree to an automatic 9% discount on the agreed-on price of a new patented medicine. The difference between the public price and the agreed-on discounted price under Germany’s AMNOG process will be reimbursed by the company.

Source: Germany inches closer to confidential pricing for drugs | pharmaphorum

Topics:

Consulting Policy Regulatory